Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has been given an average rating of “Hold” by the eight ratings firms that are currently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $41.25.
A number of analysts have issued reports on ACRS shares. ValuEngine downgraded Aclaris Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, June 6th. Cantor Fitzgerald reiterated a “buy” rating and set a $50.00 target price on shares of Aclaris Therapeutics in a research report on Monday. Jefferies Group LLC reiterated a “buy” rating and set a $36.00 target price on shares of Aclaris Therapeutics in a research report on Monday, July 31st. JMP Securities reiterated an “outperform” rating and set a $39.00 target price on shares of Aclaris Therapeutics in a research report on Friday, September 8th. Finally, BidaskClub cut Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th.
Aclaris Therapeutics (NASDAQ ACRS) traded up 0.20% on Friday, hitting $25.40. The stock had a trading volume of 275,376 shares. Aclaris Therapeutics has a 52-week low of $20.15 and a 52-week high of $33.25. The firm’s 50-day moving average is $26.09 and its 200-day moving average is $27.62. The company’s market cap is $679.09 million.
Aclaris Therapeutics (NASDAQ:ACRS) last announced its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.68) by $0.12. Equities research analysts anticipate that Aclaris Therapeutics will post ($3.10) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This piece of content was reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of United States and international copyright law. The correct version of this piece of content can be read at https://transcriptdaily.com/2017/09/19/aclaris-therapeutics-inc-acrs-receives-41-25-consensus-price-target-from-analysts.html.
In other Aclaris Therapeutics news, Director Andrew N. Schiff acquired 108,601 shares of the stock in a transaction on Wednesday, August 16th. The shares were bought at an average price of $23.02 per share, with a total value of $2,499,995.02. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 16.30% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the business. Rosenblum Silverman Sutton S F Inc. CA boosted its holdings in Aclaris Therapeutics by 17.3% in the 2nd quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 38,400 shares of the biotechnology company’s stock valued at $1,041,000 after purchasing an additional 5,650 shares in the last quarter. American International Group Inc. boosted its holdings in Aclaris Therapeutics by 31.3% in the 1st quarter. American International Group Inc. now owns 6,804 shares of the biotechnology company’s stock valued at $203,000 after purchasing an additional 1,623 shares in the last quarter. Franklin Resources Inc. boosted its holdings in Aclaris Therapeutics by 55.4% in the 2nd quarter. Franklin Resources Inc. now owns 1,955,381 shares of the biotechnology company’s stock valued at $53,030,000 after purchasing an additional 697,104 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its holdings in Aclaris Therapeutics by 6.6% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 43,961 shares of the biotechnology company’s stock valued at $1,311,000 after purchasing an additional 2,736 shares in the last quarter. Finally, EcoR1 Capital LLC boosted its holdings in Aclaris Therapeutics by 62.6% in the 1st quarter. EcoR1 Capital LLC now owns 673,100 shares of the biotechnology company’s stock valued at $20,072,000 after purchasing an additional 259,100 shares in the last quarter. 95.79% of the stock is currently owned by institutional investors.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc is a dermatologist-led, biopharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. The Company is also focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer.
Receive News & Ratings for Aclaris Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.